TCRR — TCR2 Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $58.11m
- -$52.20m
- 35
- 47
- 64
- 47
Annual cashflow statement for TCR2 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.3 | -47.6 | -67.1 | -99.8 | -152 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.85 | 6.48 | 7.79 | 13.7 | 38 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.24 | -1.1 | 0.872 | 1.62 | 9.58 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -18.7 | -41.4 | -56.7 | -81.6 | -101 |
| Capital Expenditures | -1.02 | -3.88 | -7.16 | -11.4 | -15.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -75.3 | -16.5 | -41.8 | 89.9 | -73 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -76.3 | -20.4 | -48.9 | 78.4 | -88.5 |
| Financing Cash Flow Items | -1.99 | 0 | -0.061 | -0.409 | -0.131 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 123 | 79.5 | 135 | 132 | 0.125 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 27.9 | 17.7 | 29 | 129 | -190 |